Form 8-K - Current report:
SEC Accession No. 0001815776-25-000025
Filing Date
2025-04-15
Accepted
2025-04-15 08:37:38
Documents
13
Period of Report
2025-04-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K lenz-20250415.htm   iXBRL 8-K 26434
  Complete submission text file 0001815776-25-000025.txt   156045

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lenz-20250415.xsd EX-101.SCH 1770
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lenz-20250415_lab.xml EX-101.LAB 23433
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lenz-20250415_pre.xml EX-101.PRE 13570
16 EXTRACTED XBRL INSTANCE DOCUMENT lenz-20250415_htm.xml XML 3041
Mailing Address 201 LOMAS SANTA FE DRIVE, SUITE 300 SOLANA BEACH CA 92075
Business Address 201 LOMAS SANTA FE DRIVE, SUITE 300 SOLANA BEACH CA 92075 858-925-7000
LENZ Therapeutics, Inc. (Filer) CIK: 0001815776 (see all company filings)

EIN.: 844867570 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40532 | Film No.: 25837707
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)